Public Employees Retirement System of Ohio Purchases 38,049 Shares of Halozyme Therapeutics, Inc. $HALO

Public Employees Retirement System of Ohio increased its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 6,594.3% in the 2nd quarter, HoldingsChannel reports. The fund owned 38,626 shares of the biopharmaceutical company’s stock after acquiring an additional 38,049 shares during the period. Public Employees Retirement System of Ohio’s holdings in Halozyme Therapeutics were worth $2,009,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of the company. Alliancebernstein L.P. raised its stake in shares of Halozyme Therapeutics by 4.8% during the 1st quarter. Alliancebernstein L.P. now owns 3,215,109 shares of the biopharmaceutical company’s stock worth $205,156,000 after acquiring an additional 146,677 shares in the last quarter. Congress Asset Management Co. raised its stake in shares of Halozyme Therapeutics by 8.8% during the 1st quarter. Congress Asset Management Co. now owns 2,132,707 shares of the biopharmaceutical company’s stock worth $136,088,000 after acquiring an additional 172,971 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in Halozyme Therapeutics by 4.9% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,029,160 shares of the biopharmaceutical company’s stock valued at $129,478,000 after purchasing an additional 95,600 shares in the last quarter. TD Asset Management Inc increased its stake in Halozyme Therapeutics by 5.8% during the 1st quarter. TD Asset Management Inc now owns 1,451,842 shares of the biopharmaceutical company’s stock valued at $92,642,000 after purchasing an additional 79,708 shares in the last quarter. Finally, Fuller & Thaler Asset Management Inc. increased its stake in Halozyme Therapeutics by 27.3% during the 1st quarter. Fuller & Thaler Asset Management Inc. now owns 1,130,019 shares of the biopharmaceutical company’s stock valued at $72,107,000 after purchasing an additional 242,167 shares in the last quarter. Institutional investors own 97.79% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the stock. Zacks Research upgraded shares of Halozyme Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, September 2nd. The Goldman Sachs Group assumed coverage on shares of Halozyme Therapeutics in a research note on Thursday, July 10th. They set a “neutral” rating and a $55.00 price target on the stock. Morgan Stanley upped their price target on shares of Halozyme Therapeutics from $75.00 to $80.00 and gave the company an “overweight” rating in a research note on Monday, August 18th. Wall Street Zen lowered shares of Halozyme Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Friday, September 5th. Finally, JMP Securities upped their price target on shares of Halozyme Therapeutics from $78.00 to $91.00 and gave the company a “market outperform” rating in a research note on Wednesday, August 6th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, four have assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, Halozyme Therapeutics currently has a consensus rating of “Hold” and an average price target of $70.44.

Halozyme Therapeutics Stock Down 4.3%

NASDAQ:HALO opened at $71.69 on Friday. The firm has a market capitalization of $8.39 billion, a P/E ratio of 16.41, a PEG ratio of 0.41 and a beta of 1.16. Halozyme Therapeutics, Inc. has a 1-year low of $42.01 and a 1-year high of $79.50. The company’s fifty day moving average price is $70.23 and its 200-day moving average price is $61.92. The company has a debt-to-equity ratio of 4.54, a current ratio of 8.36 and a quick ratio of 7.01.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $1.54 earnings per share for the quarter, topping analysts’ consensus estimates of $1.23 by $0.31. The firm had revenue of $325.72 million for the quarter, compared to analyst estimates of $282.66 million. Halozyme Therapeutics had a net margin of 47.28% and a return on equity of 150.85%. The business’s quarterly revenue was up 40.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.91 earnings per share. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS. As a group, equities research analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Insider Activity at Halozyme Therapeutics

In related news, CFO Nicole Labrosse sold 2,227 shares of the firm’s stock in a transaction on Monday, September 22nd. The shares were sold at an average price of $77.95, for a total transaction of $173,594.65. Following the sale, the chief financial officer owned 22,079 shares in the company, valued at approximately $1,721,058.05. This trade represents a 9.16% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Helen Torley sold 20,000 shares of the firm’s stock in a transaction on Wednesday, September 3rd. The shares were sold at an average price of $74.44, for a total transaction of $1,488,800.00. Following the sale, the chief executive officer owned 733,719 shares in the company, valued at approximately $54,618,042.36. This represents a 2.65% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 88,227 shares of company stock worth $6,020,595. 2.40% of the stock is owned by company insiders.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.